Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Arbutus Biopharma CorpABUS · Entity 4953 | Director | June 03, 2021 | June 07, 2021 |
| Damora Therapeutics, Inc.DMRA · Entity 4602 | Director | August 12, 2026 | August 13, 2026 |
| TCGX Acquisition Corp.TCGX · Entity 6504 | Director | August 04, 2026 | August 04, 2026 |
| Vera Therapeutics, Inc.VERA · Entity 4358 | Director | May 21, 2026 | May 26, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Arbutus Biopharma Corp
Report date June 03, 2021 · Filed June 07, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $2.95 · Expires 2031-06-03 | Direct | 22,000 |
Reported balance
After 2021-06-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-03 · Grant · Acquired 22,000 · Balance 22,000 F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant. F2: The options are fully vested and exercisable as of the date of the grant. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the closing price of the Company's common shares on the Nasdaq Stock Market on June 3, 2021, the date of the grant.
F2: The options are fully vested and exercisable as of the date of the grant.
Damora Therapeutics, Inc.
Report date August 12, 2026 · Filed August 13, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $31.00 · Expires 2036-08-12 | Direct | 30,350 |
Reported balance
After 2026-08-12 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-08-12 · Grant · Acquired 30,350 · Balance 30,350 F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: This option represents a right to purchase shares of common stock of the Issuer. This option will vest in equal monthly installments through August 12, 2029, subject to the Reporting Person's continued service to the Issuer on each such vesting date.
TCGX Acquisition Corp.
Report date August 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class B Ordinary SharesSEC Table II · derivative / convertible security | Direct | Not disclosed |
Reported balance
Holding disclosure · report date 2026-08-04 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance Not disclosed F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Class B Ordinary Shares will automatically convert into Class A Ordinary Shares immediately prior to, concurrently with or immediately following the consummation of the Issuer's initial business combination, or at any time prior thereto at the option of the Reporting Person, on a one-for-one basis, subject to adjustment, and have no expiration date.
Vera Therapeutics, Inc.
Report date May 21, 2026 · Filed May 26, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $34.35 · Expires 2036-05-20 | Direct | 17,084 |
Reported balance
After 2026-05-21 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-05-21 · Grant · Acquired 17,084 · Balance 17,084 F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2027 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Akero Therapeutics, Inc.
Report date December 09, 2025 · Filed December 09, 2025
Section 16 reporting ended · disclosed 2025-12-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 1
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 1 · 2025-12-09 · Disposition to issuer · Disposed 277,075 · Balance 0 F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration"). |
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 2
Sequence does not reconcile; account continuity is unresolved.
1 source rowRow 2 · 2025-12-09 · Disposition to issuer · Disposed 159,762 · Balance 0 F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU. F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-12-09 · Disposition to issuer · Disposed 3,421 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-12-09 · Disposition to issuer · Disposed 5,032 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-12-09 · Disposition to issuer · Disposed 2,328 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-12-09 · Disposition to issuer · Disposed 4,739 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-12-09 · Disposition to issuer · Disposed 3,527 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $29.23 · Expires 2034-12-16 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-12-09 · Disposition to issuer · Disposed 292,179 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $19.87 · Expires 2033-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 9
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 9 · 2025-12-09 · Disposition to issuer · Disposed 374,985 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $42.95 · Expires 2032-12-09 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 10
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 10 · 2025-12-09 · Disposition to issuer · Disposed 233,252 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 11
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 11 · 2025-12-09 · Disposition to issuer · Disposed 23,809 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 12
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 12 · 2025-12-09 · Disposition to issuer · Disposed 165,289 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.10 · Expires 2031-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 13
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 13 · 2025-12-09 · Disposition to issuer · Disposed 87,220 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.35 · Expires 2030-12-08 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 14
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 14 · 2025-12-09 · Disposition to issuer · Disposed 238,973 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $21.09 · Expires 2029-12-13 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 15
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 15 · 2025-12-09 · Disposition to issuer · Disposed 234,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $16.00 · Expires 2029-06-19 | Direct | 0 |
Reported balance
After 2025-12-09 transaction · row 16
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 16 · 2025-12-09 · Disposition to issuer · Disposed 10,000 · Balance 0 F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of October 9, 2025, among the Issuer, Novo Nordisk A/S, a Danish aktieselskab ("Novo"), and NN Invest Sub, Inc ("Merger Sub"), pursuant to which Merger Sub merged with and into the Issuer (the "Merger"), effective as of December 9, 2025 (such date and time, the "Effective Time"), with the Issuer surviving the Merger as a wholly owned subsidiary of Novo. At the Effective Time, each share of common stock of the Issuer ("Company Common Stock") reported in this Form 4 was cancelled and converted into the right to receive (i) cash in an amount equal to $54.00 (the "Closing Consideration") and (ii) one contractual contingent value right (a "CVR") representing the right to receive $6.00 in cash, if a specified milestone is achieved, pursuant to the CVR Agreement (as defined in the Merger Agreement) ((i) and (ii), together, the "Merger Consideration").
F2: Represents restricted stock units ("Company RSUs") granted to the Reporting Person. Each Company RSU represented a contingent right to receive one share of Company Common Stock upon vesting of the Company RSU.
F3: Pursuant to the Merger Agreement, at the Effective Time, each Company RSU reported in this Form 4 was deemed fully vested and cancelled and was converted into the right of the Reporting Person to receive the Merger Consideration in respect of each such Company RSU.
F4: Pursuant to the Merger Agreement, at the Effective Time, each compensatory option to purchase shares of Company Common Stock (each, a "Company Option") reported in this Form 4, whether or not vested, was deemed fully vested and was cancelled and converted into the right to receive a cash payment equal to the product of the excess of the Closing Consideration over the per share exercise price of such Company Option, multiplied by the total number of shares of Company Common Stock subject to such Company Option immediately prior to the Effective Time, plus one CVR for each share of Company Common Stock subject to such Company Option immediately prior to the Effective Time.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 02, 2024 Filed Jan 3, 2024 17:00 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 40,000 | $0.62 | $24,600.00 |
DisclosureSEC source: 0000950170-24-001053 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 590,911 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 20:37 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,628 | $20.76 | $33,797.28 |
DisclosureSEC source: 0000950170-23-071242 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 550,911 F1 · kind: Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the Reporting Person. Such sales were automatic and not at the discretion of the Reporting Person. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,405 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · derivative · entry 11 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,022 Underlying: Common Stock · 7,405 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person. F6 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 7,405 | $20.02 | $148,272.54 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · nonDerivative · entry 7 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 552,539 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.13, inclusive. Read SEC document |
| December 11, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 7,405 | $6.36 | $47,095.80 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · nonDerivative · entry 6 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 559,944 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantStock Option (Right to Buy) · Derivative | 411,936 | $0.00 Strike: $19.87 | $0.00 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · derivative · entry 10 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 411,936 Underlying: Common Stock · 411,936 shares Expires 2033-12-07 F7 · derivative.exercise_date: This option shall vest and become exercisable in forty-eight (48) equal monthly installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 12,873 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · derivative · entry 9 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,427 Underlying: Common Stock · 12,873 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person. F6 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | GrantCommon Stock | 91,541 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · nonDerivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 552,539 F4 · shares: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in eight (8) equal semi-annual installments, commencing from December 8, 2023, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 12,873 | $20.01 | $257,570.71 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,998 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.03, inclusive. Read SEC document |
| December 08, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 12,873 | $6.36 | $81,872.28 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,871 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 6,700 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · derivative · entry 8 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,300 Underlying: Common Stock · 6,700 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person. F6 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 6,700 | $20.02 | $134,125.29 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,998 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $20.00 to $20.05, inclusive. The Reporting Person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (5) to this Form 4. Read SEC document |
| December 07, 2023 Filed Dec 11, 2023 20:59 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 6,700 | $6.36 | $42,612.00 |
DisclosureSEC source: 0000950170-23-069504 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,698 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the Reporting Person. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:41 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0000950170-23-052057 · ownership.xml · derivative · entry 7 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F7 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:41 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 6,470 | $50.56 | $327,135.49 |
DisclosureSEC source: 0000950170-23-052057 · ownership.xml · nonDerivative · entry 6 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,998 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F6 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $50.25 to $50.96, inclusive. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:41 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,700 | $49.71 | $84,500.03 |
DisclosureSEC source: 0000950170-23-052057 · ownership.xml · nonDerivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 467,468 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F5 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.17 to $50.05, inclusive. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:41 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 2,662 | $48.56 | $129,275.24 |
DisclosureSEC source: 0000950170-23-052057 · ownership.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 469,168 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $48.16 to $49.11, inclusive. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:41 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 5,300 | $46.88 | $248,483.08 |
DisclosureSEC source: 0000950170-23-052057 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 471,830 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.54 to $47.50, inclusive. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:41 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 8,868 | $46.06 | $408,433.48 |
DisclosureSEC source: 0000950170-23-052057 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 477,130 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.50 to $46.46, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) through (6) to this Form 4. Read SEC document |
| October 02, 2023 Filed Oct 4, 2023 20:41 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $6.36 | $159,000.00 |
DisclosureSEC source: 0000950170-23-052057 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 485,998 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| September 13, 2023 Filed Sep 25, 2023 20:36 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,682 | $50.34 | $84,671.88 |
DisclosureSEC source: 0000950170-23-049768 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 460,998 F1 · kind: Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted stock units. The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the reporting person. The sales reported on this Form 4 represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. Such sales were automatic and intended to qualify under Rule 10b5-1. Read SEC document |
| September 01, 2023 Filed Sep 18, 2023 18:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0000950170-23-048632 · ownership.xml · derivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F3 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| September 01, 2023 Filed Sep 18, 2023 18:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 127 | $50.24 | $6,380.48 |
DisclosureSEC source: 0000950170-23-048632 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,680 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| September 01, 2023 Filed Sep 18, 2023 18:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 24,873 | $49.77 | $1,237,867.03 |
DisclosureSEC source: 0000950170-23-048632 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 462,807 F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $49.19 to $50.02, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnote (2) to this Form 4. Read SEC document |
| September 01, 2023 Filed Sep 18, 2023 18:48 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $6.36 | $159,000.00 |
DisclosureSEC source: 0000950170-23-048632 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 487,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions were effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| August 30, 2023 Filed Aug 30, 2023 19:04 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-23-045550 · ownership.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 102,212 Underlying: Common Stock · 15,000 shares Expires 2028-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| August 30, 2023 Filed Aug 30, 2023 19:04 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 15,000 | $0.62 | $9,225.00 |
DisclosureSEC source: 0000950170-23-045550 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:13 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0000950170-23-037989 · ownership.xml · derivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F4 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:13 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 11,321 | $43.52 | $492,702.37 |
DisclosureSEC source: 0000950170-23-037989 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 447,680 F1 · kind: The reported transactions was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.31 to $43.73, inclusive. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:13 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 13,679 | $42.85 | $586,164.30 |
DisclosureSEC source: 0000950170-23-037989 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 459,001 F1 · kind: The reported transactions was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $42.30 to $43.295, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
| August 01, 2023 Filed Aug 3, 2023 16:13 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $6.36 | $159,000.00 |
DisclosureSEC source: 0000950170-23-037989 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 472,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:44 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0000950170-23-032113 · ownership.xml · derivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 115,000 Underlying: Common Stock · 25,000 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F5 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:44 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,219 | $46.29 | $56,427.02 |
DisclosureSEC source: 0000950170-23-032113 · ownership.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 447,680 F1 · kind: The reported transactions was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $46.01 to $46.52, inclusive. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:44 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 5,051 | $45.36 | $229,120.94 |
DisclosureSEC source: 0000950170-23-032113 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 448,899 F1 · kind: The reported transactions was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.94, inclusive. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:44 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 18,730 | $44.66 | $836,493.04 |
DisclosureSEC source: 0000950170-23-032113 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 453,950 F1 · kind: The reported transactions was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.00 to $44.99, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| July 03, 2023 Filed Jul 6, 2023 20:44 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 25,000 | $6.36 | $159,000.00 |
DisclosureSEC source: 0000950170-23-032113 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 472,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transactions was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 19:12 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 40,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-23-030253 · ownership.xml · derivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,212 Underlying: Common Stock · 40,000 shares Expires 2028-09-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| June 27, 2023 Filed Jun 27, 2023 19:12 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 40,000 | $0.62 | $24,600.00 |
DisclosureSEC source: 0000950170-23-030253 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 447,680 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2023 Filed Jun 15, 2023 21:38 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 1,613 | $55.16 | $88,973.08 |
DisclosureSEC source: 0000899243-23-015673 · doc4.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 407,680 F1 · kind: The Issuer has adopted a "sell-to-cover" policy to satisfy the tax withholding obligations of the reporting person. The sales reported on this Form 4 represent the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of restricted share units. Such sales were automatic and intended to qualify under Rule 10b5-1. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 3,670 | $0.00 Strike: $6.36 | $0.00 |
DisclosureSEC source: 0000950170-23-026462 · ownership.xml · derivative · entry 7 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 3,670 shares Expires 2029-01-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F5 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 21,330 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000950170-23-026462 · ownership.xml · derivative · entry 6 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 64,538 Underlying: Common Stock · 21,330 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F5 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 400 | $45.90 | $18,358.80 |
DisclosureSEC source: 0000950170-23-026462 · ownership.xml · nonDerivative · entry 5 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,293 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.795 to $45.99, inclusive. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 20,686 | $45.26 | $936,169.75 |
DisclosureSEC source: 0000950170-23-026462 · ownership.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,693 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.74 to $45.72, inclusive. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 3,914 | $44.18 | $172,901.73 |
DisclosureSEC source: 0000950170-23-026462 · ownership.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 430,379 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $43.72 to $44.61, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 3,670 | $6.36 | $23,341.20 |
DisclosureSEC source: 0000950170-23-026462 · ownership.xml · nonDerivative · entry 2 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 434,293 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| June 01, 2023 Filed Jun 5, 2023 18:23 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionCommon Stock | 21,330 | $0.62 | $13,117.95 |
DisclosureSEC source: 0000950170-23-026462 · ownership.xml · nonDerivative · entry 1 Cheng Andrew · CIK 0001778307 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 430,623 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. Read SEC document |
| May 10, 2023 Filed May 12, 2023 20:11 UTC | Vera Therapeutics, Inc. VERA · Entity 4358 | GrantStock Option (right to buy) · Derivative | 20,000 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001209191-23-029008 · doc4.xml · derivative · entry 1 Cheng Andrew · CIK 0001778307 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Class A Common Stock · 20,000 shares Expires 2033-05-09 F1 · derivative.exercise_date: The shares subject to the option will vest in full on the earlier of the first anniversary of the grant date or the date of the Company's 2024 annual stockholder meeting, subject to the Reporting Person's continuous service through such vesting date. Notwithstanding the foregoing, the shares will vest in full upon a change in control, subject to the Reporting Person's continuous service through the date of such change in control. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:28 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | Exercise / conversionStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $0.62 | $0.00 |
DisclosureSEC source: 0000899243-23-012167 · doc4.xml · derivative · entry 6 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 85,868 Underlying: Common Stock · 25,000 shares Expires 2028-10-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F4 · derivative.exercise_date: The options are vested and currently exercisable. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:28 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 3,477 | $45.50 | $158,219.15 |
DisclosureSEC source: 0000899243-23-012167 · doc4.xml · nonDerivative · entry 4 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 409,293 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $45.41 to $45.73, inclusive. Read SEC document |
| May 01, 2023 Filed May 3, 2023 20:28 UTC | Akero Therapeutics, Inc. AKRO · Entity 71984 | SaleCommon Stock | 21,523 | $45.00 | $968,640.46 |
DisclosureSEC source: 0000899243-23-012167 · doc4.xml · nonDerivative · entry 3 Cheng Andrew · CIK 0001778307 · Director · President & CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 412,770 F1 · kind: The reported transaction was effected pursuant to a Rule 10b5-1 trading plan dated November 14, 2022, as amended on January 10, 2023, previously adopted by the reporting person. F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $44.41 to $45.40, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2) and (3) to this Form 4. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.